Proactive regulator

Credibility of an approved vaccine should be ensured

On Wednesday, the subject expert committee (SEC) that is advising India’s drug regulator, the Drug Controller General of India (DGCI), on the development and approval of vaccines for Covid-19 met with two of the major players in India’s vaccine race. These two were the representatives of Bharat Biotech, which is testing an indigenously developed vaccine candidate, and the Pune-based Serum Institute of India, which is the licensee for the vaccine developed by AstraZeneca and Oxford University. It is good news that the SEC is engaging closely with the vaccine developers even before it is officially required for the DGCI to